# Perfuse Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perfuse-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: http://perfusetherapeutics.com
- Total disclosed funding: $9M
- Latest round: Series A (Jul 15, 2020)
- Investors on record: 4

## About

Perfuse Therapeutics, Inc. focuses on developing innovative therapies to enhance retinal blood flow for treating ocular diseases, such as glaucoma and diabetic retinopathy, through advanced pharmacological solutions.Perfuse Therapeutics is dedicated to creating therapies that improve blood flow to the retina to combat critical ocular diseases. Founded by Sevgi Gurkan, the company is headquartered in San Francisco, US. In July 2020, Perfuse Therapeutics raised USD 9.00 mn in Series A funding, bringing its total funding to USD 9.00 mn, with a current company valuation of USD 32.21 mn. The recent funding round included investors such as Catalio Capital Management, Hatteras Venture Partners, Lilly Asia Ventures, and OrbiMed Advisors.Perfuse Therapeutics specializes in developing innovative therapies aimed at enhancing blood flow to the retina, targeting critical ocular diseases such as glaucoma and diabetic retinopathy. Their core offering is a first-in-class endothelin antagonist designed to mitigate the effects of ischemia in ocular tissues, addressing the underlying pathologies associated with these conditions. This product is particularly relevant for patients suffering from open-angle glaucoma and diabetic retinopathy, with a focus on serving markets with high prevalence rates of these diseases.The revenue model for Perfuse Therapeutics is centered around the commercialization of its flagship endothelin antagonist. This model is likely structured through partnerships with healthcare providers and distributors within the ophthalmology sector, facilitated via B2B relationships with hospitals, clinics, and specialty pharmacies. The company aims to ensure accessibility of its product to patients while implementing pricing strategies reflective of the therapeutic value offered to healthcare systems.Perfuse Therapeutics plans to leverage its Series A funding of USD 9.00 mn, raised in July 2020, to support the development of upcoming products targeting new therapeutic areas within ocular diseases. The company also aims to expand its market presence, focusing on regions with a high incidence of glaucoma and diabetic retinopathy. These strategic initiatives are expected to enhance the company's capacity to deliver innovative therapeutic solutions to its target market.

## Funding rounds

- Series A, Jul 15, 2020, $9M — OrbiMed Advisors, Hatteras Venture Partners, Lilly Asia Ventures, Catalio Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A